Fresh Genetic Tool Predicts Inherited Risk for Eight Cardiovascular Conditions
Cardiovascular disease remains the leading cause of death worldwide, often striking patients who don’t fit the traditional profile of “high risk.” However, a breakthrough in genomic medicine is changing how clinicians identify vulnerable patients. Researchers have developed and validated a new integrated polygenic risk score (PRS) framework capable of predicting a person’s inherited risk for eight different cardiovascular conditions.
Published on April 29, 2026, in the Journal of the American College of Cardiology (JACC), the study demonstrates that this genetic risk report can aid doctors implement earlier interventions—such as medication or lifestyle changes—for patients with a high genetic predisposition to heart and vascular diseases.
What is a Polygenic Risk Score?
Unlike traditional genetic testing, which often looks for a single high-impact mutation (like those found in familial hypercholesterolemia), a polygenic risk score (PRS) looks at the bigger picture. Most common diseases aren’t caused by one “broken” gene but by the cumulative effect of thousands of tiny variations across the entire genome.
The new tool uses an elastic-net approach called PRSmix to analyze these variations. By aggregating these small signals, the test provides a comprehensive estimate of a patient’s inherited susceptibility to specific cardiovascular traits.
Eight Conditions, One Comprehensive Report
The researchers developed the PRS using genomic data from the National Institutes of Health’s (NIH) All of Us Research Program. The tool specifically evaluates the risk for the following eight conditions:
- Coronary artery disease (CAD)
- Type 2 diabetes (T2D)
- Atrial fibrillation (AFib)
- Venous thromboembolism (VTE)
- Thoracic aortic aneurysm (TAA)
- Extreme hypertension
- Severe hypercholesterolemia
- Elevated lipoprotein(a) (Lp[a])
Validating the Results: The Mass General Brigham Study
To ensure the tool worked in a real-world clinical setting, researchers validated the PRS using participants from the Mass General Brigham Biobank. The validation cohort included 53,306 genotyped participants from a multihospital academic health system, with a mean age of 53 years (56% women and 55% European ancestry).
The results were striking. Patients in the highest genetic risk category—the top 10% of the PRS distribution (or the top 20% for the rarer TAA and VTE)—showed significantly higher odds of developing these diseases compared to those with average genetic risk. Specifically, the observed odds ratios were:
- 3.7 for coronary artery disease
- 3.1 for type 2 diabetes
- 3 for atrial fibrillation
From Data to the Doctor’s Office
A common hurdle in genomic medicine is the “translation gap”—the distance between a research discovery and a usable clinical tool. This new framework is designed to be implementable and is already available as a clinically orderable test through the Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine.
The goal is to move away from a “one size fits all” approach to prevention. By identifying high-risk individuals early, clinicians can personalize screening schedules and intensify preventive therapies before a cardiovascular event occurs.
“Interpreting DNA risk is new for the public as well as clinicians,” explained co-senior author Pradeep Natarajan, MD, director of Preventive Cardiology at Mass General Brigham Heart and Vascular Institute and associate member at the Broad Institute of MIT and Harvard. “It was exceptionally important to us to provide a clear genetic risk report that would be accessible and patient friendly.”
- Comprehensive Screening: The tool predicts risk for eight different cardiovascular conditions simultaneously.
- High Accuracy: Patients in the top 10% of genetic risk for CAD had 3.7 times the odds of disease compared to average-risk individuals.
- Clinical Availability: The test is currently available to clinicians across the U.S. Via Broad Clinical Labs and Mass General Brigham.
- Preventive Focus: The report aims to trigger earlier lifestyle and medical interventions for high-risk patients.
Frequently Asked Questions
Does a high PRS mean I will definitely develop heart disease?
No. A polygenic risk score measures inherited susceptibility, not a guaranteed diagnosis. Genetic risk is only one piece of the puzzle; environmental factors, diet, exercise, and existing health conditions also play critical roles in whether a disease actually develops.
How is this different from a family history check?
Family history is a useful proxy for genetic risk, but it’s often incomplete or unknown. A PRS provides a precise, data-driven measurement of your actual genetic makeup, identifying risks that may not be apparent in your family tree.
Who should consider this test?
This tool is particularly valuable for individuals who may not have traditional risk factors (like high blood pressure or smoking) but have a family history of heart disease, or for clinicians looking to refine their prevention strategies for patients.
The Future of Cardiovascular Prevention
The shift toward integrated polygenic risk reporting marks a move toward truly personalized medicine. As these tools become more integrated into standard care, the focus of cardiology will likely shift further from treating established disease to preventing it entirely by targeting the most genetically vulnerable individuals years before symptoms appear.